A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Recruiting · NCT05892718 · Registry updated 2026-02-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-02-04 | NCT05892718 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| FBD Biologics Limited | 7 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Carolina Biooncology | Huntersville | United States | 2 |
| Greenville Hospital System University Medical Center (ITOR) | Greenville | United States | 2 |
| Hangzhou First People's Hospital | Hangzhou | China | 6 |
| Hematology-Oncology Associates of the Treasure Coast | Port Saint Lucie | United States | 1 |
| National Taiwan University Hospital | Taipei | Taiwan | 159 |
| Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare | New Taipei City | Taiwan | 3 |
| Taipei Veterans General Hospital | Taipei | Taiwan | 189 |
| UT Southwestern Medical Center | Dallas | United States | 210 |